The Personalized Medicine Middle: Coalition Sends Consensus Concepts To Hill
This article was originally published in The Gray Sheet
Executive Summary
What can diagnostic firms, drug companies, physicians, insurers, researcher centers and patient advocacy groups all agree on when it comes to policies to support personalized medicine?
You may also be interested in...
FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail
FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.
AdvaMedDx Steps Into Public Sphere: Director Details Diagnostics Priorities
The recently established diagnostics arm of AdvaMed had what its executive director called a coming out party last week.
Personalized Medicine Coalition Renews Pitch For Modern Coding System
Medicare coding is outdated and too general for today’s molecular diagnostics. And the resulting uncertainty about how to code and adequately pay for the next-generation tests hampers investment and innovation in the field, according to a lobbying paper released Dec. 7 by the Personalized Medicine Coalition.